Traumatic Brain INjury — IL-1ra Dose-range Study for Moderate-to-severe TBI Patients
Citation(s)
A Randomised Double Blind Placebo Controlled Dose-range Study Using Placebo, 1.5g and 3.0g of Intravenous Recombinant Interleukin-1 Receptor Antagonist (Anakinra) for Patients With Moderate-to-severe TBI